ARTHEx Biotech CEO Frédéric Legros (L) and co-founder Beatriz Llamusí
May 3, 2023 07:00 AM EDT
Financing
Startups

ARTHEx nabs Se­ries B for clin­i­cal tri­al of ASO in my­oton­ic dy­s­tro­phy as Ver­tex’s deals heat up the space

Kyle LaHucik

Senior Reporter

ARTHEx Biotech has raised €42 mil­lion (about $46 mil­lion) in Se­ries B funds to bankroll an ear­ly-stage study of a drug can­di­date in my­oton­ic dy­s­tro­phy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times